Intrauterine growth restriction (IUGR) is a major cause of perinatal death and neonatal morbidity and mortality.
Introduction
The placenta is an extraembryonic tissue that is situated between maternal and fetal compartments and acts to ensure the normal progression of fetal development. This task is achieved through regulating nutrient and waste transport and modulating the maternal environment through the elaboration of an assortment of hormones, growth factors, and other regulatory molecules. Understanding mechanisms underlying the growth and development of the placenta is paramount to any appreciation of fetal development.
The rat chorioallantoic placenta is organized into two compartments: the junctional zone and the labyrinth zone. The junctional zone is comprised of stem cells and three differentiated cell types: (i) trophoblast giant cells, (ii) spongiotrophoblast cells, and (iii) glycogen cells. Trophoblast giant cells arise by endoreduplication, are situated at the maternal-placental interface, and are one of the major endocrine cells of the placenta (Soares et al. 1996) . They synthesize and secrete steroid and peptide hormones. Spongiotrophoblast cells are located immediately beneath the trophoblast giant cell layer and synthesize and secrete peptide hormones. Glycogen cells are a transient cell type embedded among the spongiotrophoblast cells. Beyond their accumulation of glycogen, their biology is not well understood. The labyrinth zone is located at the fetal interface and is comprised of stem cells capable of differentiating into trophoblast giant cells or fusing to form syncytial trophoblast cells. The labyrinthine trophoblast giant cells possess a restricted capacity for hormone production (Soares et al. 1996) , whereas syncytial trophoblast cells mediate the transfer of nutrients and wastes between maternal and fetal compartments (Knipp et al. 1999) . The composition of the trophoblastic elements within each zone changes through pregnancy. Each trophoblast lineage of the placenta develops specialized functions required for successful pregnancy. Disruptions in trophoblast development can lead to early pregnancy loss or intrauterine growth restriction (IUGR). These represent serious health problems whose etiologies are not sufficiently understood. Differentiation of trophoblast cells can be monitored by their endocrine activities, which include expression of members of the prolactin (PRL) gene family (Dai et al. 2002) . PRL gene family members have been implicated for their roles in the regulation of maternal adaptation to pregnancy (Soares & Linzer 2001 , Soares 2004 .
Synthetic glucocorticoids, including dexamethasone, have been used for over three decades to mature fetal lungs and prevent respiratory distress syndrome in pregnancies where delivery is likely before 34 weeks (Liggins & Howie 1972 , Trainer 2002 . Although glucocorticoids promote lung maturation, these actions are not without negative side effects. Exposure to glucocorticoids retards fetal growth in animal models and in humans (Seckl 1994 , Gluckman 2001 . In rats, fetal-placental exposure to maternally administered glucocorticoids decreases birth weight and placental weight (Benediktsson et al. 1993 , Sugden & Langdown 2001 , McDonald et al. 2003 . The mechanism underlying the placental growth inhibitory effects of dexamethasone have not been elucidated.
Insulin-like growth factor (IGF)-II is a potential target for glucocorticoid actions on placental development. Evidence exists that glucocorticoids regulate IGF-II expression in a variety of cell types and tissues using both in vitro and in vivo models (Levinovitz & Norstedt 1989 , Cheng et al. 1998 , Smink et al. 2002 and IGF-II is viewed as a key autocrine/paracrine placental growth factor (DeChiara et al. 1990 , Barker et al. 1993 . In the mouse, IGF-II null mutations lead to significant IUGR of both the fetus and placenta (DeChiara et al. 1990 , Lopez et al. 1996 . The rodent placenta possesses all the components of the IGF-II signaling pathway (Zhou & Bondy 1992 , Barker et al. 1993 , Lopez et al. 1996 .
Both IGF-I and IGF-II act on their target cells via interactions and activation of the IGF receptor type I (IGFR-I) (Nakae et al. 2001) . Phosphatidylinositol 3-kinase (PI3-kinase) signaling pathway is a downstream effector of IGFR-I receptor signaling (Kulik & Weber 1998 , Moorehead et al. 2001 . PI3-kinase signals through several pleckstrin homology domain containing regulatory proteins, including the Ser/Thr protein kinase, Akt (also called protein kinase B) (Chan et al. 1999 , Datta et al. 1999 . Akt activation can stimulate changes in gene transcription, cell survival, cell division, and cell differentiation.
In the present report we examined the effects of dexamethasone on the placental phenotype and demonstrate that compromised placental growth following dexamethasone treatment is associated with dysregulated placental PRL family gene expression and downregulation of the IGF-II/Akt signaling pathway leading to increases in indices of placental apoptosis.
Materials and Methods

Animals and tissue preparation
Holtzman rats were obtained from Harlan SpragueDawley Inc. (Indianapolis, IN, USA) . To obtain timed pregnancies, females were caged overnight with fertile males. The presence of sperm in the vaginal smear was designated as day 0 of pregnancy. On day 13 of pregnancy, pregnant rats were subcutaneously injected with a bolus dose of 100 µg dexamethasone acetate (Sigma, St Louis, MO, USA) in 0·1 ml 10% ethanol. Another group of gestation day 13 pregnant rats was injected with the vehicle only and used as controls. Animals were then anesthetized with halothane, and an alzet osmotic pump (model # 2 ML1, Durect Corp., Cupertino, CA, USA) was subcutaneously implanted. The osmotic pumps were calibrated to release 200 µg dexamethasone acetate/kg maternal body weight/day. Control rats received osmotic pumps containing vehicle. Four animals were used in each group. Animals were killed on day 20 of pregnancy. We selected this route and dose of dexamethasone treatment because it was previously demonstrated to cause IUGR in the rat (Benediktsson et al. 1993 , Levitt et al. 1996 , Sugden & Langdown 2001 . Placental tissues (junctional zone and labyrinth zone) were dissected from pregnant animals. Tissues were snap-frozen in liquid nitrogen for PRL family mini-array and Northern and Western analysis. For in situ hybridization, tissues were frozen in dry ice-cooled heptane. All tissue samples were stored at -80 C until used. The University of Kansas Medical Center Animal Care and Use Committee approved all procedures for handling and experimentation with rodents.
PRL family mini-array assay
The PRL family mini-array assay, a hybridization-based tool for simultaneously monitoring expression of each member of the rat PRL family (Dai et al. 2002) , was used to monitor trophoblast endocrine function. The PRL family mini-array assay was performed as previously described (Dai et al. 2002 , Ain et al. 2003 . Twenty nanograms PCR-amplified cDNA for each of the members of the rat PRL family were spotted, in duplicate, onto nylon membranes. Membranes were crosslinked and stored at 4 C until used. Total RNA was extracted from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). [ P 32 ]dCTP-labeled cDNA probes were generated by reverse transcription using 5 µg total RNA. Total RNA was isolated from two pooled and randomly selected placentas per uterus from each animal. A total of four samples were analyzed per treatment group. Probes were purified using micro bio-spin columns (Bio-Rad Laboratories, Richmond, CA, USA). Membrane filters were briefly rinsed with water and pre-hybridized for 2 h at 42 C with 5 SSPE (1 SSPE is 0·18 M NaCl, 10 mM NaH 2 PO 4 , 10 mM EDTA, pH 7·4) containing 5 Denhardt's reagent, 50% deionized formamide, 1% SDS, and salmon sperm DNA (100 µg/ml). Hybridizations were performed overnight with the labeled probes at 42 C. Membranes were washed once with 2 SSPE and 0·1% SDS for 30 min at 42 C and twice with 0·1 SSPE and 0·5% SDS at 60 C for 30 min each. Membranes were then wrapped with plastic wrap and exposed to Kodak Bio-Max film (Kodak, Rochester, NY, USA) for 1-4 h and developed.
Northern blot analysis
Northern blot analysis was performed as described previously (Faria et al. 1990) . Total RNA was extracted from tissues using TRIzol reagent (Invitrogen). Total RNA (20 µg/lane) was resolved in 1% formaldehyde-agarose gels, transferred to nylon membranes, and crosslinked. Blots were probed with P 32 -labeled cDNAs for PRL-like protein-B (PLP-B), PLP-C, placental lactogen-Iv (PL-Iv), PL-II (Dai et al. 2002) and IGF-II. Glyceraldehyde-3 -phosphate dehydrogenase (G3 PDH) cDNA was used to evaluate the integrity and equal loading of RNA samples. At least three different tissue samples from three different animals were analyzed with each probe.
In situ hybridization
In situ hybridization was performed as described previously (Ain et al. 2003 (Ain et al. , 2004 . Ten-micron cryosections of tissues were prepared and stored at -80 C until used. Plasmids containing cDNAs for rat PLP-C, PL-II and IGF-II were used as templates to synthesize sense and anti-sense digoxigenin-labeled riboprobes according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN, USA). Tissue sections were air dried and fixed in ice-cold 4% paraformaldehyde in phosphatebuffered saline (PBS) for 15 min. Pre-hybridization was carried out in a humidified chamber at 50 C in 5 SSC (standard saline citrate), 50% deionized formamide, 1 Denhardt's reagent, 10% dextran sulfate and salmon sperm DNA (100 µg/ml). Hybridizations were performed in the same incubation conditions overnight. Slides were washed in 2 SSC at room temperature for 30 min followed by treatment with RNase-A (100 ng/ml) and additional washes with 2 SSC for 30 min at room temperature, 2 SSC for 1 h at 65 C, and 0·1 SSC for 1 h at 65 C. Tissue samples were then blocked for 30 min and incubated with alkaline phosphatase-conjugated antidigoxigenin antibody (1:500) in blocking buffer (Roche Molecular Biochemicals) for 2 h at room temperature. Slides were then washed and detection was performed using nitro blue tetrazolium (250 µg/ml) and 5-bromo-4-chloro-3-indolyl-phosphate (225 µg/ml; Roche Molecular Biochemicals).
Western blot analysis
Tissues were homogenized in a Tris saline buffer (50 mM Tris, 150 mM NaCl, pH 7·4, containing 1% NP-40, 1 mM EDTA, 0·1 mg/ml PMSF, and a protease inhibitor cocktail; Sigma). Samples were then centrifuged and the supernatants collected. Protein concentrations were determined for each sample using the Bio-Rad DC protein assay (Bio-Rad (PARP, cat. no. 9542) . Antibodies were diluted to 1:1000 either in blocking solution or in TBST containing 5% bovine serum albumin (BSA). After washing the membranes in TBST, the blots were incubated with horseradish peroxidaseconjugated goat anti-rabbit IgG (Cell Signaling) diluted 1:2000 in blocking solution for one hour at room temperature. After washing with TBST, bound antibodies were detected by chemiluminescence (ECL kit; Amersham Pharmacia Biotech, Piscataway, NJ, USA). Blots were then stripped using stripping buffer (Pierce Chemical Co., Rockford, IL, USA) and re-probed using -actin antibody (Sigma) using the above protocol.
Statistical analysis
The data were analyzed by analysis of variance. The source of variation from significant F ratios was determined with the Newman-Keuls multiple comparison test (Keppel 1973) .
Results
Maternal dexamethasone administration influences fetal and placental development and placental hormone production
Similar to previous reports, dexamethasone administration during the last third of gestation resulted in both fetal (Fig. 1A, P<0·01 ) and placental growth restriction (Fig. 1B, P<0·01, and Fig. 1C) . Additionally, maternal body weight gain was affected by dexamethasone treatment (control, 59 7 g versus dexamethasone, 34 3 g, P<0·01). Dexamethasone treatment did not affect litter size (number of fetuses) or fetal viability.
The junctional zone of the chorioallantoic placenta is the primary source of members of the PRL family of hormones/cytokines during the last week of pregnancy, whereas the labyrinth zone makes a lesser contribution. The PRL family mini-array hybridization assay was used to survey placental responses to maternal dexamethasone exposure. Maternal dexamethasone treatment resulted in the dysregulation of PRL family gene expression in both regions of the chorioallantoic placenta (Fig. 2) . In general, if affected, PRL family gene expression was inhibited in the junctional zone, whereas PRL family gene expression was stimulated in the labyrinth zone. The inhibitory effect of dexamethasone on junctional zone gene expression was best exemplified by monitoring PLP-B mRNA levels, whereas in the labyrinth zone PLP-C mRNA showed the most dramatic response (Fig. 2) . Northern blot analyses were used to further validate the expression of the PRL gene family in the placenta (Fig. 3A) . Maternal dexamethasone treatment dramatically inhibited junctional zone PLP-B transcripts. PL-II showed modest changes in either placental zone following dexamethasone treatment (Fig. 3A, B and C) . The influence of dexamethasone on the expression of PLP-C transcripts was dependent on the placental zone. Dexamethasone treatment had minimal effects on PLP-C mRNA levels in the junctional zone, in contrast to a dramatic upregulation of labyrinthine PLP-C mRNA levels (Figs 2 and 3) .
The expression of PLP-C in the labyrinth zone is an aberration, which prompted an investigation of the cellular site of PLP-C expression. Tissue distributions of PLP-C mRNAs were monitored by in situ hybridization (Fig. 3D) . Expression of PL-II was used as a control as its expression was not substantially altered by dexamethasone treatment and is restricted to trophoblast giant cells of the junctional and labyrinth zones. PLP-C transcripts were not detectable by in situ hybridization in the labyrinth zone of the placenta from the control group. Maternal dexamethasone treatment resulted in the detection of colonies of PLP-C mRNA-positive cells in the labyrinth zone. Morphologically, the cells in these colonies resembled spongiotrophoblast cells of the junctional zone. In summary, maternal dexamethasone affected placental development and hormone/cytokine gene expression.
Dexamethasone regulates IGF-II mRNA expression by the placenta
In the next series of experiments, we sought to account for the intrauterine placental growth retardation. Initially, we examined the effect of maternal dexamethasone treatment on placental IGF-II expression. Northern blot analysis showed that there was a prominent decrease in IGF-II mRNA concentrations in junctional zones from dexamethasone-treated animals ( Fig. 4A and B) . Maternal dexamethasone treatment had only modest effects on IGF-II expression in the labyrinth zone (Fig. 4A, B) . In situ hybridization of placental IGF-II mRNA expression corroborated the Northern blot analysis (Fig. 4C) . IGF-II signaling is critical to placental development (DeChiara et al. 1990 , Barker et al. 1993 . Thus, maternal dexamethasone-associated placental growth restriction may be mediated, at least in part, by decreased placental IGF-II.
Dexamethasone down-regulates Akt signaling pathway and increases indices of placental apoptosis
IGFs act, at least in part, through the PI3-kinase/Akt signaling pathway (Kulik & Weber 1998 , Moorehead et al. 2001 . Thus, we examined the effects of maternally administered dexamethasone on placental Akt signaling. Junctional zone lysates from control and dexamethasone-treated groups were subjected to immunoblot analysis. Activation of the Akt pathway is associated with phosphorylation of Akt on Ser 473 . Maternal dexamethasone treatment led to a significant decrease in Akt activation (Fig. 5A and B) . Total Akt protein expression was not significantly affected by the treatment (Fig. 5A) . We next examined a downstream effector of Akt, BAD, a known regulator of apoptosis. Phosphorylation of BAD on Ser 136 by activated Akt prevents apoptosis. Consistent with the deactivation of Akt, we observed that maternal dexamethasone treatment also resulted in decreased phosphorylated BAD without affecting total BAD protein ( Fig. 5C and D) . These results suggest that pathways preventing apoptosis in the junctional zone might be disrupted in the dexamethasone-exposed placentas. Thus, we monitored the integrity of the junctional zone using cleaved PARP as a measure of apoptosis (Lazebnik et al. 1994) . As shown in Fig. 5E and F, dexamethasone treatment was associated with an increased accumulation of the 89-kDa PARP cleavage product when compared with controls. Blots were stripped and re-probed with -actin to show that equal amounts of protein were loaded in each lane (Fig. 5E ). Maternally administered dexamethasone leads to attenuated placental Akt signaling and increases in at least one measure of placental apoptosis, PARP cleavage.
Discussion
In most species, size of the fetus is proportional to placental size. When the size of the placenta is restricted, as in maternal malnutrition or compromised placental blood flow, the fetus is also often growth restricted (Price et al. 1992) . A poorly developed or inefficiently functioning placenta is associated with a reduction in birth weight. In this report, we investigated the effect of maternally administered dexamethasone on placental development and function. We chose a dose and route of dexamethasone administration that reproducibly induces IUGR in rats (Benediktsson et al. 1993 , Sugden & Langdown 2001 , McDonald et al. 2003 .
Pregnancy-dependent adjustments in maternal and fetal compartments are orchestrated by the endocrine function of trophoblast cells (Soares et al. 1996) . As trophoblast cells differentiate they acquire the capacity to produce hormones, cytokines, and growth factors, including members of the PRL family (Soares & Linzer 2001 , Soares 2004 . Maternal dexamethasone treatment resulted in the dysregulation of PRL family gene expression and compromised placental development. Dexamethasone negatively impacted production of members of the PRL family associated with the junctional zone, especially the spongiotrophoblast-specific PLP-B mRNAs. In contrast, the effect of dexamethasone on the labyrinth zone was highlighted by a marked increase in expression of PLP-C. PLP-C is not normally expressed in the labyrinth zone (Dai et al. 2002) . Labyrinthine PLP-C was attributed to spongiotrophoblast-like cellular colonies inappropriately developing in the labyrinth zone of the dexamethasonetreated rats. PRL family hormones/cytokines participate in the regulation of maternal and fetal adaptations to pregnancy (Soares & Linzer 2001 , Soares 2004 . Whether dysregulated PRL family gene expression patterns contribute directly or indirectly to the placental and/or fetal IUGR remain to be determined.
Disruptions in spongiotrophoblast cell development may be central to the placental endocrine phenotype induced by maternal dexamethasone treatment. Interestingly, dysmorphic development of spongiotrophoblast cells is also a characteristic of interspecies hybrid and cloned placentas (Rogers & Dawson 1970 , Zechner et al. 1996 , Kurz et al. 1999 , Tanaka et al. 2001 . Abnormalities in genomic imprinting are implicated in these placental pathologies (Zechner et al. 2002 , Schutt et al. 2003 , Shi et al. 2004 , Singh et al. 2004 . There is some evidence for imprinting among members of the placental PRL family in Peromyscus (Vrana et al. 2001) ; however, experimentation on imprinting within the rat PRL family locus has not been reported. Imprinting is fundamental to the regulation of IGF-II, which was also affected by maternal dexamethasone treatment in our study. IGF-II is one of many genes exhibiting allele-specific expression with an impact on placental development. A more generalized influence of maternal dexamethasone treatment on the process of genomic imprinting in the developing placenta and fetus has not been reported.
The effect of dexamethasone on placental IGF-II expression provides for a logical explanation of the IUGR. Our data showed that maternal dexamethasone-induced IUGR was associated with decreased expression of IGF-II by the junctional zone of the placenta. IGF-II null mutations in mice are known to cause fetal and placental growth restriction (DeChiara et al. 1990) .
IGFs affect cellular function, at least in part, through the PI3-kinase pathway (Kulik & Weber 1998 , Moorehead et al. 2001 . Akt is one of the principal downstream mediators of PI3-kinase action (Datta et al. 1999 , Richards 2001 , Downward 2004 . We observed that maternal dexamethasone treatment was associated with decreased placental Akt activation. Of the three Akt family members, Akt1 is most abundantly expressed in the placenta (Kamei et al. 2002 , Yang et al. 2003 . Akt1 null mice are growth restricted due, in part, to placental insufficiency (Chen et al. 2001 , Cho et al. 2001 , Yang et al. 2003 . Our findings are also consistent with earlier studies showing that the PI3-kinase/Akt pathway modulates trophoblast cell endocrine differentiation, including expression of the PRL gene family (Kamei et al. 2002) .
Akt impacts an array of cellular processes, including cell survival (Chen et al. 2001 , Vivanco & Sawyers 2002 , Yang et al. 2003 , Downward 2004 , Brazil et al. 2004 ) and influences cell survival, in part, through phosphorylation of the proapoptotic protein, BAD (Datta et al. 1997 , 1999 , del Peso et al. 1997 , Downward 1999 , Bergmann 2002 , Jiang et al. 2003 . Phosphorylation of BAD prevents its association with Bcl-2 or Bcl-X L , leaving these proteins free to exert their antiapoptotic function (Yang et al. 1995 , Zha et al. 1996 . In our experimentation, maternal dexamethasone treatment diminished junctional zone placental Akt activation, which was associated with decreased BAD phosphorylation and increased PARP cleavage, an indicator of apoptosis. These findings are consistent with earlier experimentation showing maternal dexamethasone increases apoptosis, as measured by TUNEL activity, within the junctional zone of the rat placenta (Waddell et al. 2000) .
In summary, maternal dexamethasone-induced IUGR is associated with placental insufficiency, dysregulation of placental hormone production, and inhibition of placental IGF-II and Akt signaling. Based on the literature presented above, it is reasonable to presume that some or all of these events may be linked; however, establishing causal relationships will require additional experimentation.
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